ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lilly Licenses A Drug From Glenmark

November 5, 2007 | APPEARED IN VOLUME 85, ISSUE 45

Eli Lilly & Co. will pay Glenmark Pharmaceuticals $45 million up front and a possible $215 million more in milestones for a portfolio of molecules called transient receptor potential vanilloid subfamily 1 (TRPV1) antagonists, which are being developed in a range of pain indications. Lilly gains North American, European, and Japanese marketing rights to GRC 6211, Glenmark's lead TRPV1 antagonist, currently in Phase II trials to treat osteoarthritic pain. Mumbai-based Glenmark started out as a formulations and bulk drug manufacturing company but, in 2001, made a major push into drug discovery. It already has licensing deals with Merck KGaA and Forest Laboratories.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment